awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q35677661-4F2D00D7-170D-44E7-9D7A-DF454104FF7B
Q35677661-4F2D00D7-170D-44E7-9D7A-DF454104FF7B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35677661-4F2D00D7-170D-44E7-9D7A-DF454104FF7B
A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours.
P2860
Q35677661-4F2D00D7-170D-44E7-9D7A-DF454104FF7B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35677661-4F2D00D7-170D-44E7-9D7A-DF454104FF7B
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
846cfa14bf570129a4b45addc2dca9af9de19c1c
P2860
An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours.